JP2000517299A5 - - Google Patents

Download PDF

Info

Publication number
JP2000517299A5
JP2000517299A5 JP1998508981A JP50898198A JP2000517299A5 JP 2000517299 A5 JP2000517299 A5 JP 2000517299A5 JP 1998508981 A JP1998508981 A JP 1998508981A JP 50898198 A JP50898198 A JP 50898198A JP 2000517299 A5 JP2000517299 A5 JP 2000517299A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998508981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000517299A (ja
Filing date
Publication date
Priority claimed from US08/688,613 external-priority patent/US5958892A/en
Application filed filed Critical
Publication of JP2000517299A publication Critical patent/JP2000517299A/ja
Publication of JP2000517299A5 publication Critical patent/JP2000517299A5/ja
Ceased legal-status Critical Current

Links

JP10508981A 1996-07-30 1997-07-24 癌細胞における2―メトキシエストラジオール誘導アポトーシス Ceased JP2000517299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688,613 1996-07-30
US08/688,613 US5958892A (en) 1996-07-30 1996-07-30 2-methoxyestradiol-induced apoptosis in cancer cells
PCT/US1997/012998 WO1998004291A1 (en) 1996-07-30 1997-07-24 2-methoxyestradiol-induced apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
JP2000517299A JP2000517299A (ja) 2000-12-26
JP2000517299A5 true JP2000517299A5 (enExample) 2005-04-07

Family

ID=24765087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508981A Ceased JP2000517299A (ja) 1996-07-30 1997-07-24 癌細胞における2―メトキシエストラジオール誘導アポトーシス

Country Status (8)

Country Link
US (3) US5958892A (enExample)
EP (1) EP0921821B1 (enExample)
JP (1) JP2000517299A (enExample)
AT (1) ATE279212T1 (enExample)
AU (1) AU723401B2 (enExample)
CA (1) CA2262533A1 (enExample)
DE (1) DE69731213T2 (enExample)
WO (1) WO1998004291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EA003326B1 (ru) * 1998-12-02 2003-04-24 Пфайзер Продактс Инк. Способ лечения рака
US6548541B1 (en) * 1999-04-21 2003-04-15 Unitech Pharmaceuticals, Inc. Carboplatin analogs for cancer treatment
EP1175219A1 (en) * 1999-05-12 2002-01-30 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US7691567B2 (en) 2000-10-30 2010-04-06 Board Of Regents, The University Of Texas System Methods and compositions relating to fortilin, an anti-apoptotic molecule, and modulators of fortilin
WO2002062348A1 (en) * 2001-02-05 2002-08-15 Oncology Sciences Corporation Eugenol, optionally in combination with 2-methoxyestradiol, as a cancer chemopreventative agent
EP1373215B1 (en) * 2001-03-30 2006-07-26 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Geldanamycin derivatives useful for treating cancer
WO2003063791A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
PL217626B1 (pl) 2002-07-18 2014-08-29 Helix Biopharma Corp Kompozycja farmaceutyczna do zastosowania w leczeniu raka
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US6979675B2 (en) * 2003-01-10 2005-12-27 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7160908B2 (en) * 2003-03-04 2007-01-09 Unitech Pharmaceuticals, Inc. Dynamic anticancer platinum compounds
JP2006526025A (ja) * 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
JP2007529426A (ja) * 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1791546A2 (en) * 2004-09-13 2007-06-06 PR Pharmaceuticals Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
WO2006058298A2 (en) * 2004-11-29 2006-06-01 Entremed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2007227256B2 (en) * 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US9029322B2 (en) 2007-06-05 2015-05-12 Cornell University Compounds for enhancing p21 expression and methods of use thereof
KR20090009637A (ko) * 2007-07-20 2009-01-23 삼성전자주식회사 엠비-오에프디엠 시스템 및 프레임 바운더리 검출 방법
SG11201803768WA (en) 2015-10-08 2018-06-28 Univ Utah Res Found Methods and compositions for preventing or treating cancer
KR101837735B1 (ko) * 2016-08-08 2018-04-19 성균관대학교산학협력단 TCTP (Translationally controlled tumour protein) 단백질을 포함하는 난모세포(oocytes) 노화 방지 또는 수정능력 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
ATE161039T1 (de) 1988-10-31 1997-12-15 Univ California Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
EP0390323B2 (en) 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
IE911115A1 (en) 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ES2157109T3 (es) 1993-02-16 2001-08-01 Onyx Pharma Inc Virus citopaticos para el tratamiento y la profilasis de la neoplasia.
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
BR9405507A (pt) 1993-07-13 1999-05-25 Rhone Poulenc Rorer Sa Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000517304A5 (enExample)
JP2000516561A5 (enExample)
JP2000500076A5 (enExample)
JP2001503008A5 (enExample)
JP2000513357A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000504267A5 (enExample)
JP2000502472A5 (enExample)
JP2000500874A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000517299A5 (enExample)
JP2000501876A5 (enExample)
JP2000512095A5 (enExample)
JP2000513111A5 (enExample)
JP2000501229A5 (enExample)
JP2000500857A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)
JP2000508049A5 (enExample)